BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Subbaiah MAM. Triple Reuptake Inhibitors as Potential Therapeutics for Depression and Other Disorders: Design Paradigm and Developmental Challenges. J Med Chem 2018;61:2133-65. [DOI: 10.1021/acs.jmedchem.6b01827] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
Number Citing Articles
1 Paudel S, Min X, Acharya S, Khadka DB, Yoon G, Kim K, Cheon SH. Design, synthesis, and systematic evaluation of 4-arylpiperazine- and 4-benzylpiperidine napthyl ethers as inhibitors of monoamine neurotransmitters reuptake. Bioorganic & Medicinal Chemistry 2018;26:5538-46. [DOI: 10.1016/j.bmc.2018.09.033] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Shang L, Duan C, Chang S, Chang N, Jia S. Antidepressant-like effects of dezocine in mice: involvement of 5-HT1A and κ opioid receptors. Behav Pharmacol 2021;32:472-8. [PMID: 34101632 DOI: 10.1097/FBP.0000000000000641] [Reference Citation Analysis]
3 Zhu H, Wang W, Sha C, Guo W, Li C, Zhao F, Wang H, Jiang W, Tian J. Pharmacological Characterization of Toludesvenlafaxine as a Triple Reuptake Inhibitor. Front Pharmacol 2021;12:741794. [PMID: 34594228 DOI: 10.3389/fphar.2021.741794] [Reference Citation Analysis]
4 Guo W, Gao Y, Jiang W, Li C, Lin F, Zhu H, Wang H, Ye L, Qi JG, Cen X, Tian J. Toxicity effects of a novel potent triple reuptake inhibitor, LPM570065, on the fertility and early embryonic development in Sprague-Dawley rats. Regul Toxicol Pharmacol 2018;100:45-51. [PMID: 30359699 DOI: 10.1016/j.yrtph.2018.10.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
5 Osborne DM, Sandau US, Jones AT, Vander Velden JW, Weingarten AM, Etesami N, Huo Y, Shen HY, Boison D. Developmental role of adenosine kinase for the expression of sex-dependent neuropsychiatric behavior. Neuropharmacology 2018;141:89-97. [PMID: 30145320 DOI: 10.1016/j.neuropharm.2018.08.025] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
6 Wen H, Qin W, Yang G, Guo Y. Design and Synthesis of Arylamidine Derivatives as Serotonin/Norepinephrine Dual Reuptake Inhibitors. Molecules 2019;24:E497. [PMID: 30704101 DOI: 10.3390/molecules24030497] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 Li C, Jiang W, Gao Y, Lin F, Zhu H, Wang H, Ye L, Qi JG, Tian J. Acute, subchronic oral toxicity, and genotoxicity evaluations of LPM570065, a new potent triple reuptake inhibitor. Regul Toxicol Pharmacol 2018;98:129-39. [PMID: 30030102 DOI: 10.1016/j.yrtph.2018.07.011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
8 Cheng B, Morstein J, Ladefoged LK, Maesen JB, Schiøtt B, Sinning S, Trauner D. A Photoswitchable Inhibitor of the Human Serotonin Transporter. ACS Chem Neurosci 2020;11:1231-7. [PMID: 32275382 DOI: 10.1021/acschemneuro.9b00521] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
9 Matt SM, Gaskill PJ. Dopaminergic impact of cART and anti-depressants on HIV neuropathogenesis in older adults. Brain Res 2019;1723:146398. [PMID: 31442412 DOI: 10.1016/j.brainres.2019.146398] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
10 Tu G, Fu T, Yang F, Yang J, Zhang Z, Yao X, Xue W, Zhu F. Understanding the Polypharmacological Profiles of Triple Reuptake Inhibitors by Molecular Simulation. ACS Chem Neurosci 2021;12:2013-26. [PMID: 33977725 DOI: 10.1021/acschemneuro.1c00127] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Li Z, Chen J, Wu L, Ren A, Lu P, Wang Y. Preparation of 4-Diazoisoquinolin-3-ones via Dimroth Rearrangement and Their Extension to 4-Aryltetrahydroisoquinolin-3-ones. Org Lett 2020;22:26-30. [DOI: 10.1021/acs.orglett.9b03708] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 3.7] [Reference Citation Analysis]
12 Xue W, Fu T, Zheng G, Tu G, Zhang Y, Yang F, Tao L, Yao L, Zhu F. Recent Advances and Challenges of the Drugs Acting on Monoamine Transporters. CMC 2020;27:3830-76. [DOI: 10.2174/0929867325666181009123218] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
13 Xue W, Wang P, Tu G, Yang F, Zheng G, Li X, Li X, Chen Y, Yao X, Zhu F. Computational identification of the binding mechanism of a triple reuptake inhibitor amitifadine for the treatment of major depressive disorder. Phys Chem Chem Phys 2018;20:6606-16. [DOI: 10.1039/c7cp07869b] [Cited by in Crossref: 48] [Cited by in F6Publishing: 16] [Article Influence: 12.0] [Reference Citation Analysis]
14 Zhao S, Zang ZL, Li S, Wen X, Wang C, Guo J, He Y. Iridium-Catalyzed Cycloisomerization of N-Tethered 1,7-Enynes: Construction of an Azabicyclo[5.1.0]octene System. J Org Chem 2020;85:9321-30. [PMID: 32551602 DOI: 10.1021/acs.joc.0c00516] [Reference Citation Analysis]